Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysis

BMC Systems Biology

Volumn 5, Issue , 2011, Pages

  Vempati, Prakash ^a   Popel, Aleksander S ^a   Mac Gabhann, Feilim ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ANIMAL; ARTICLE; BIOLOGY; CELL MEMBRANE; CHEMISTRY; COMPUTER; COMPUTER PROGRAM; DIFFUSION; EXTRACELLULAR MATRIX; HUMAN; KINETICS; METABOLISM; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PROTEIN BINDING;

ALTERNATIVE SPLICING; ANIMALS; CELL MEMBRANE; COMPUTATIONAL BIOLOGY; COMPUTERS; DIFFUSION; EXTRACELLULAR MATRIX; HUMANS; KINETICS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; PROTEIN ISOFORMS; SOFTWARE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955380395     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-5-59     Document Type: Article

References (95)

1. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999, 5:495-502. 10.1038/8379, 10229225.
2. Mattot V, Moons L, Lupu F, Chernavvsky D, Gomez RA, Collen D, Carmeliet P. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002, 13:1548-1560. 10.1097/01.ASN.0000013925.19218.7B, 12039984.
3. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001, 116:838-845. 10.1309/FXNL-QTN1-94FH-AB3A, 11764072.
4. Ng YS. The Biology of Vascular Endothelial Cell Growth Factor Isoforms. VEGF in Development 2008, Ruhrberg C: Landis Bioscience.
5. Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997, 94:12081-12087. 10.1073/pnas.94.22.12081, 23709, 9342366.
6. Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol 2000, 20:7282-7291. 10.1128/MCB.20.19.7282-7291.2000, 86282, 10982845.
7. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691. 10.1083/jcb.200409115, 2171712, 15911882.
8. Mac Gabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol 2007, 292:H459-474.
9. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation 2008, 15:715-738. 10.1080/10739680802095964, 2722038, 18608994.
10. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395. 10.1038/74651, 10742145.
11. Chappell JC, Taylor SM, Ferrara N, Bautch VL. Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell 2009, 17:377-386. 10.1016/j.devcel.2009.07.011, 2747120, 19758562.
12. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177. 10.1083/jcb.200302047, 2172999, 12810700.
13. Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002, 16:2684-2698. 10.1101/gad.242002, 187458, 12381667.
14. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches. PLoS Comput Biol 2006, 2:e180. 10.1371/journal.pcbi.0020180, 1761657, 17196035.
15. Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, Fontijn RD, David G, Hommes DW, Lamers CB, Sier CF. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008, 44:1904-1913. 10.1016/j.ejca.2008.06.031, 18691882.
16. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744. 10.1038/35036374, 2852586, 11025665.
17. Lundkvist A, Lee S, Iruela-Arispe L, Betsholtz C, Gerhardt H. Growth factor gradients in vascular patterning. Novartis Found Symp 2007, 283:194-201. discussion 201-196, 238-141.
18. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623-633. 514591, 15343380.
19. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 2001, 98:12485-12490. 10.1073/pnas.171460498, 60080, 11606713.
20. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 2006, 103:12493-12498. 10.1073/pnas.0601807103, 1531646, 16891410.
21. Mitchell CA, Rutland CS, Walker M, Nasir M, Foss AJ, Stewart C, Gerhardt H, Konerding MA, Risau W, Drexler HC. Unique vascular phenotypes following over-expression of individual VEGFA isoforms from the developing lens. Angiogenesis 2006, 9:209-224. 10.1007/s10456-006-9056-7, 17109192.
22. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
23. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996, 271:7788-7795. 10.1074/jbc.271.13.7788, 8631822.
24. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326. 275767, 8167412.
25. Tozer GM, Akerman S, Cross NA, Barber PR, Bjorndahl MA, Greco O, Harris S, Hill SA, Honess DJ, Ireson CR, et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 2008, 68:2301-2311. 10.1158/0008-5472.CAN-07-2011, 18381437.
26. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000, 19:2138-2146. 10.1038/sj.onc.1203533, 10815805.
27. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745. 10.1016/S0092-8674(00)81402-6, 9529250.
28. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271:10079-10086. 10.1074/jbc.271.17.10079, 8626565.
29. Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae JO, Huang J, Fisher J, Lefkowitch JH, Feirt N, Rudge J, et al. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 2008, 6:1-9. 10.1158/1541-7786.MCR-07-0101, 18234958.
30. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005, 24:4037-4051.
31. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002, 277:36288-36295. 10.1074/jbc.M201674200, 12114504.
32. Ito TK, Ishii G, Chiba H, Ochiai A. The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells. Oncogene 2007, 26:7194-7203. 10.1038/sj.onc.1210535, 17525740.
33. Ito TK, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, Ochiai A. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009, 113:2363-2369. 10.1182/blood-2008-08-172742, 18974372.
34. Kawamura H, Li X, Goishi K, van Meeteren LA, Jakobsson L, Cebe-Suarez S, Shimizu A, Edholm D, Ballmer-Hofer K, Kjellen L, et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 2008,
35. Chen TT, Luque A, Lee S, Anderson SM, Segura T, Iruela-Arispe ML. Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol 2010, 188:595-609. 10.1083/jcb.200906044, 2828913, 20176926.
36. Nakatsu MN, Sainson RC, Perez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, Carpenter PM, Hughes CC. VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 2003, 83:1873-1885. 10.1097/01.LAB.0000107160.81875.33, 14691306.
37. Herve MA, Buteau-Lozano H, Vassy R, Bieche I, Velasco G, Pla M, Perret G, Mourah S, Perrot-Applanat M. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol 2008, 172:167-178. 10.2353/ajpath.2008.070181, 2189622, 18079435.
38. Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS, Shima DT. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem 2007, 282:28045-28056. 10.1074/jbc.M700319200, 17626017.
39. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000, 83:63-68. 2374542, 10883669.
40. Mac Gabhann F, Ji JW, Popel AS. Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol 2006, 2:e127. 10.1371/journal.pcbi.0020127, 1570371, 17002494.
41. Mac Gabhann F, Ji JW, Popel AS. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J Appl Physiol 2007, 102:722-734.
42. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol 2008, 2:77. 10.1186/1752-0509-2-77, 2562372, 18713470.
43. Wu FT, Stefanini MO, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS One 2009, 4:e5108. 10.1371/journal.pone.0005108, 2663039, 19352513.
44. Vempati P, Mac Gabhann F, Popel AS. Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model. PloS ONE 2010, 5:e11860. 10.1371/journal.pone.0011860, 2912330, 20686621.
45. Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-Lavigne M, Koch AW, Watts RJ. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007, 282:24049-24056. 10.1074/jbc.M703554200, 17575273.
46. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997, 272:13390-13396. 10.1074/jbc.272.20.13390, 9148962.
47. Karagiannis ED, Popel AS. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem 2004, 279:39105-39114. 10.1074/jbc.M403627200, 15252025.
48. Karagiannis ED, Popel AS. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J Theor Biol 2006, 238:124-145. 10.1016/j.jtbi.2005.05.020, 16005020.
49. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 2007, 282:37585-37596. 10.1074/jbc.M611500200, 17848556.
50. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. Physiol Genomics 2009, 38:29-41. 10.1152/physiolgenomics.00031.2009, 2696151, 19351908.
51. Mineur P, Colige AC, Deroanne CF, Dubail J, Kesteloot F, Habraken Y, Noel A, Voo S, Waltenberger J, Lapiere CM, et al. Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J Cell Biol 2007, 179:1261-1273. 10.1083/jcb.200703052, 2140032, 18086921.
52. Kicheva A, Pantazis P, Bollenbach T, Kalaidzidis Y, Bittig T, Julicher F, Gonzalez-Gaitan M. Kinetics of morphogen gradient formation. Science 2007, 315:521-525. 10.1126/science.1135774, 17255514.
53. Serini G, Ambrosi D, Giraudo E, Gamba A, Preziosi L, Bussolino F. Modeling the early stages of vascular network assembly. EMBO J 2003, 22:1771-1779. 10.1093/emboj/cdg176, 154468, 12682010.
54. Makarenkova HP, Hoffman MP, Beenken A, Eliseenkova AV, Meech R, Tsau C, Patel VN, Lang RA, Mohammadi M. Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis. Sci Signal 2009, 2:ra55. 10.1126/scisignal.2000304, 2884999, 19755711.
55. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical Recipes in C++: Art of Scientific Computing 2002, New York: Cambridge University Press, 2.
56. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci 2002, 43:3500-3510.
57. Yuan F, Krol A, Tong S. Available space and extracellular transport of macromolecules: effects of pore size and connectedness. Ann Biomed Eng 2001, 29:1150-1158.
58. Berk DA, Yuan F, Leunig M, Jain RK. Fluorescence photobleaching with spatial Fourier analysis: measurement of diffusion in light-scattering media. Biophys J 1993, 65:2428-2436. 10.1016/S0006-3495(93)81326-2, 1225983, 8312481.
59. Ramanujan S, Pluen A, McKee TD, Brown EB, Boucher Y, Jain RK. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J 2002, 83:1650-1660. 10.1016/S0006-3495(02)73933-7, 1302261, 12202388.
60. Filion RJ, Popel AS. Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. Am J Physiol Heart Circ Physiol 2005, 288:H263-279.
61. Fogh-Andersen N, Altura BM, Altura BT, Siggaard-Andersen O. Composition of interstitial fluid. Clin Chem 1995, 41:1522-1525.
62. Lauffenburger DA, Linderman JJ. Receptors: Models for Binding, Trafficking, and Signaling. Receptors 1993, 144-151. New York: Oxford University Press, Inc.
63. Dowd CJ, Cooney CL, Nugent MA. Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem 1999, 274:5236-5244. 10.1074/jbc.274.8.5236, 9988774.
64. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem 2004, 279:12346-12354.
65. Cebe-Suarez S, Grunewald FS, Jaussi R, Li X, Claesson-Welsh L, Spillmann D, Mercer AA, Prota AE, Ballmer-Hofer K. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB J 2008, 22:3078-3086. 10.1096/fj.08-107219, 18467594.
66. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2004, 286:H153-164.
67. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007, 97:978-985. 10.1038/sj.bjc.6603923, 2360423, 17912242.
68. Barkefors I, Le Jan S, Jakobsson L, Hejll E, Carlson G, Johansson H, Jarvius J, Park JW, Li Jeon N, Kreuger J. Endothelial cell migration in stable gradients of vascular endothelial growth factor A and fibroblast growth factor 2: effects on chemotaxis and chemokinesis. J Biol Chem 2008, 283:13905-13912. 10.1074/jbc.M704917200, 18347025.
69. Shamloo A, Ma N, Poo MM, Sohn LL, Heilshorn SC. Endothelial cell polarization and chemotaxis in a microfluidic device. Lab Chip 2008, 8:1292-1299. 10.1039/b719788h, 18651071.
70. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res 2008, 102:637-652. 10.1161/CIRCRESAHA.107.167171, 18369162.
71. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002, 72:20-32. 10.1067/mcp.2002.126179, 12152001.
72. Robinson GS, Ju M, Shih SC, Xu X, McMahon G, Caldwell RB, Smith LE. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J 2001, 15:1215-1217.
73. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988, 107:743-751. 10.1083/jcb.107.2.743, 2115214, 2971068.
74. Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. Dev Dyn 2004, 231:503-509. 10.1002/dvdy.20148, 15376331.
75. Roth D, Piekarek M, Paulsson M, Christ H, Bloch W, Krieg T, Davidson JM, Eming SA. Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol 2006, 168:670-684. 10.2353/ajpath.2006.050372, 1606492, 16436680.
76. Lauer G, Sollberg S, Cole M, Flamme I, Sturzebecher J, Mann K, Krieg T, Eming SA. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol 2000, 115:12-18. 10.1046/j.1523-1747.2000.00036.x, 10886501.
77. Fantin A, Maden CH, Ruhrberg C. Neuropilin ligands in vascular and neuronal patterning. Biochem Soc Trans 2009, 37:1228-1232. 10.1042/BST0371228, 19909252.
78. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue--beyond blood vessels. Exp Neurol 2004, 187:246-253. 10.1016/j.expneurol.2004.01.022, 15144851.
79. Williams RS, Annex BH. Plasticity of myocytes and capillaries: a possible coordinating role for VEGF. Circ Res 2004, 95:7-8. 10.1161/01.RES.0000136345.81719.37, 15242980.
80. Gu C, Rodriguez ER, Reimert DV, Shu T, Fritzsch B, Richards LJ, Kolodkin AL, Ginty DD. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 2003, 5:45-57. 10.1016/S1534-5807(03)00169-2, 12852851.
81. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, Guldberg RE, Mooney DJ. Integrated approach to designing growth factor delivery systems. FASEB J 2007, 21:3896-3903. 10.1096/fj.06-7873com, 17644610.
82. Lauer G, Sollberg S, Cole M, Krieg T, Eming SA. Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett 2002, 531:309-313. 10.1016/S0014-5793(02)03545-7, 12417332.
83. Bollenbach T, Kruse K, Pantazis P, Gonzalez-Gaitan M, Julicher F. Morphogen transport in epithelia. Phys Rev E Stat Nonlin Soft Matter Phys 2007, 75:011901.
84. Eldar A, Rosin D, Shilo BZ, Barkai N. Self-enhanced ligand degradation underlies robustness of morphogen gradients. Dev Cell 2003, 5:635-646. 10.1016/S1534-5807(03)00292-2, 14536064.
85. Zoeller JJ, Whitelock JM, Iozzo RV. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol 2009, 28:284-291. 10.1016/j.matbio.2009.04.010, 2705690, 19422911.
86. Stollman TH, Scheer MG, Franssen GM, Verrijp KN, Oyen WJ, Ruers TJ, Leenders WP, Boerman OC. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 2009, 24:195-200. 10.1089/cbr.2008.0574, 19409041.
87. Qutub AA, Popel AS. Elongation, proliferation & migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst Biol 2009, 3:13. 10.1186/1752-0509-3-13, 2672076, 19171061.
88. Qutub AA, Mac Gabhann F, Karagiannis ED, Vempati P, Popel AS. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag 2009, 28:14-31.
89. Bentley K, Gerhardt H, Bates PA. Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. J Theor Biol 2008, 250:25-36. 10.1016/j.jtbi.2007.09.015, 18028963.
90. Small AR, Neagu A, Amyot F, Sackett D, Chernomordik V, Gandjbakhche A. Spatial distribution of VEGF isoforms and chemotactic signals in the vicinity of a tumor. J Theor Biol 2008, 252:593-607. 10.1016/j.jtbi.2008.02.009, 18395755.
91. Jabbarzadeh E, Abrams CF. Strategies to enhance capillary formation inside biomaterials: a computational study. Tissue Eng 2007, 13:2073-2086. 10.1089/ten.2006.0057, 17590150.
92. Milde F, Bergdorf M, Koumoutsakos P. A hybrid model for three-dimensional simulations of sprouting angiogenesis. Biophys J 2008, 95:3146-3160. 10.1529/biophysj.107.124511, 2547461, 18586846.
93. Bauer AL, Jackson TL, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol 2009, 5:e1000445. 10.1371/journal.pcbi.1000445, 2709079, 19629173.
94. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001, 220:112-121. 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D, 11169844.
95. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000, 275:26690-26695.